Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

scientific article

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. is …
instance of (P31):
meta-analysisQ815382
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2014-06-583369
P932PMC publication ID4319239
P698PubMed publication ID25422100
P5875ResearchGate publication ID268875055

P50authorOliver W PressQ50211588
Muhammad A MirQ57616746
Sergei SyrbuQ59690735
Brian K LinkQ61054699
Matthew J. MaurerQ74084050
Susan L SlagerQ92530010
P2093author name stringStephen M Ansell
William R Macon
James R Cerhan
Jonathan W Friedberg
Michael LeBlanc
Thomas Witzig
Steven C Ziesmer
Thomas Habermann
Anne Novak
P2860cites workMYD88 L265P somatic mutation in Waldenström's macroglobulinemia.Q27851888
Extracting summary statistics to perform meta-analyses of the published literature for survival endpointsQ27860640
Chemokines, chemokine receptors, and cancer metastasisQ28297436
Oncogenically active MYD88 mutations in human lymphomaQ28301648
The many roles of chemokines and chemokine receptors in inflammationQ29618880
Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infectionQ33777159
IL-4 protein expression and basal activation of Erk in vivo in follicular lymphomaQ34198061
Chemokines: roles in leukocyte development, trafficking, and effector functionQ34203393
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.Q34646321
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphomaQ35031964
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphomaQ35212373
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaQ35858092
Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis.Q35866406
The clinical course of follicular lymphomaQ36031839
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.Q36195016
Stromal cell contribution to human follicular lymphoma pathogenesis.Q36208267
Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control studyQ36354265
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.Q36628291
Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohortQ36680965
Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironmentQ37051364
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphomaQ37083956
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experienceQ37083964
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology ResourceQ37132380
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disordersQ37265471
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphomaQ37402310
Chemokines in cancer related inflammationQ37816561
Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.Q38112911
Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtypeQ39257959
Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cellsQ39733717
IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in miceQ39788067
Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and NutritionQ39869706
IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndromeQ40133010
Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patientsQ44460966
Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive diseaseQ45028553
Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvementQ45258119
Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.Q45937516
Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.Q46531281
Improved survival of follicular lymphoma patients in the United States.Q50764033
Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.Q52574053
Predictive value of prognostic indices in patients with follicular lymphomas.Q53241661
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.Q53251676
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium.Q53261993
Follicular lymphoma international prognostic index.Q53289840
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.Q53330746
The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.Q53342545
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune CellsQ57279527
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cellsQ60609607
Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcomeQ60685678
Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseasesQ67992322
Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failureQ72178748
Expression of chemokine receptor CXCR3 and its ligand, mig, in gastric and thyroid marginal zone lymphomas. Possible migration and autocrine mechanismQ73251449
Serum concentration of the soluble interleukin-2 receptor in vitiligo patientsQ77361391
Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patientsQ79297583
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphomaQ79405030
Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?Q80206065
Meta-analysis to evaluate the role of interferon in follicular lymphomaQ81346749
Prognosis of follicular lymphomasQ82717691
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectanakinraQ415411
P304page(s)992-998
P577publication date2014-11-24
P1433published inBloodQ885070
P1476titleElevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
P478volume125

Reverse relations

cites work (P2860)
Q92429945An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients
Q42153043Application of mid-infrared (MIR) microscopy imaging for discrimination between follicular hyperplasia and follicular lymphoma in transgenic mice
Q38850729Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma
Q45931583CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Q37429985CXCL9: evidence and contradictions for its role in tumor progression
Q50099990Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.
Q26773194Diagnosis of follicular lymphoma of the gastrointestinal tract: A better initial diagnostic workup
Q64244584Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial
Q102071906Expression and role of MIG/CXCR3 axis in mantle cell lymphoma
Q38873898Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis
Q47756618Gastrointestinal follicular lymphoma: Current knowledge and future challenges
Q52562303Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides.
Q39901834Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma
Q58793783Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
Q51055200Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Q52865502Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Q28073262Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How
Q33722638Systemically Infused Mesenchymal Stem Cells Show Different Homing Profiles in Healthy and Tumor Mouse Models
Q92879880The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment
Q50710717Unmet needs in the first-line treatment of follicular lymphoma.

Search more.